Bunge's $34 billion Viterra merger stalled by US-China trade rift, Bloomberg reports

Reuters
05-02
UPDATE 3-Bunge's $34 billion Viterra merger stalled by US-China trade rift, Bloomberg reports

Adds Viterra's response in paragraph 2

May 2 (Reuters) - Bunge Global's BG.N $34 billion merger with Glencore-backed GLEN.L Viterra is being stalled by trade tensions between the United States and China, Bloomberg News reported on Friday, citing people familiar with the matter.

"We are in the final stage of regulatory approval. We express our continued gratitude for the constructive dialogue with Chinese government officials throughout the regulatory review process," Bunge and Viterra said in separate emailed responses to Reuters.

The merger was first announced in 2023. If finalized, it will create a global crop trading and processing giant closer in scale to chief rivals Archer-Daniels-Midland ADM.N and Cargill [RIC:RIC:CARG.UL].

Regulatory approval in China is among the last remaining hurdles to the deal's closing.

Bunge has said it has obtained most global approvals required for the merger - which was initially expected to close in mid-2024 - including in the European Union and Canada.

Bunge executives and advisers are growing increasingly concerned that the political rift between the two countries will hold up the process further, according to the report.

Bunge CEO Greg Heckman made several trips to China for discussions with authorities, the Bloomberg report said. It also said Chinese regulators have flagged concerns that the merger would increase industry concentration and potentially impact Beijing's food security interests.

The relevant regulators are conducting a careful compliance review given the deal's significance, according to the report.

(Reporting by Vallari Srivastava in Bengaluru; Editing by Anil D'Silva, Pooja Desai and Tasim Zahid)

((Srivastava.Vallari@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10